Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis

Bianca Weinstock-Guttman1,2,5*, Murali Ramanathan1,3, Karen Marr4, David Hojnacki1, Ralph HB Benedict1, Charity Morgan2, Eluen Ann Yeh1, Ellen Carl3, Cheryl Kennedy4, Justine Reuther4, Christina Brooks4, Kristin Hunt3, Makki Elfadil4, Michelle Andrews4 and Robert Zivadinov1,4

Abstract

Background: Chronic cerebrospinal venous insufficiency (CCSVI) is a vascular condition characterized by anomalies of the primary veins outside the skull that has been reported to be associated with MS. In the blinded Combined Transcranial (TCD) and Extracranial Venous Doppler Evaluation (CTEVD) study, we found that prevalence of CCSVI was significantly higher in multiple sclerosis (MS) vs. healthy controls (HC) (56.1% vs. 22.7%, \( p < 0.001 \)). The objective was to evaluate the clinical correlates of venous anomalies indicative of CCSVI in patients with MS.

Methods: The original study enrolled 499 subjects; 163 HC, 289 MS, 21 CIS and 26 subjects with other neurological disorders who underwent a clinical examination and a combined Doppler and TCD scan of the head and neck. This analysis was restricted to adult subjects with MS (RR-MS: \( n = 181 \), SP-MS: \( n = 80 \) and PP-MS: \( n = 12 \)). Disability status was evaluated by using the Kurtzke Expanded Disability Status Scale (EDSS) and MS severity scale (MSSS).

Results: Disability was not associated with the presence (\( \geq 2 \) venous hemodynamic criteria) or the severity of CCSVI, as measured with venous hemodynamic insufficiency severity score (VHISS). However, the severity of CCSVI was associated with the increased brainstem functional EDSS sub-score (\( p = 0.002 \)). In logistic regression analysis, progressive MS (SP-MS or PP-MS) vs. non-progressive status (including RR-MS) was associated with CCSVI diagnosis (\( p = 0.004 \), OR = 2.34, CI = 1.3–4.2).

Conclusions: The presence and severity of CCVSI in multiple sclerosis correlate with disease status but has no or very limited association with clinical disability.

Search terms: Multiple sclerosis, Disease progression, Disability, Echo-color Doppler, Venous anomalies, CCSVI

Background

Multiple sclerosis (MS) is considered a chronic disease of the brain and spinal cord characterized by inflammatory-demyelinating and neurodegenerative features that coexist from early stages [1,2]. The heterogeneous clinical presentation and dissimilar long-term outcomes support a complex MS pathobiology. The recent findings of Zamboni et al. [3-5], who identified a strong association between MS and a condition defined as chronic cerebrospinal venous insufficiency (CCSVI) provide a different viewpoint on the possible cause and progression of MS. However, the relationship of CCSVI to MS pathogenesis is unproven, and sensitivity/specificity findings have ranged from perfect [3] to intermediate [6-13] to null association [14-19]. These contradictory research findings have fueled a polarizing controversy between practitioners and MS patients [20-23]. Therefore a critical objective independent validation of the existence of CCSVI in MS patients and certainly establishing whether CCSVI is a cause, consequence or mere association with MS becomes imperative.

CCSVI has been described as a vascular condition characterized by anomalies of the main extra-cranial cerebrospinal (CS) venous routes that interfere with normal CS venous outflow. These anomalies have been reported to affect the internal jugular veins (IJV), the vertebral veins (VV) and the azygous vein (AZY), and can be detected using a noninvasive combined venous
echo-color ultrasound and transcranial (ECD/TCD) Doppler and confirmed by selective venography [3-5]. It has been hypothesized that CS venous anomalies may cause alterations to blood flow that eventually result in iron deposition, decreased brain parenchyma metabolism, degeneration of neurons and characteristic brain injury patterns found in MS [24,25].

In an independent study [9] using identical EC/TCD method as described by Zamboni, our group showed recently a significant association between MS and presence of CCSVI compared to a healthy control group ($p<0.001$). The goal of the present additional analysis within the initial large heterogeneous MS cohort was to determine the associations of venous hemodynamic findings according to the Zamboni CCSVI criteria with clinical disease severity and classification of disease status as relapsing or progressive.

**Methods**

**Study population**

**Ethics statement**

The study was approved by the University at Buffalo Human Subjects Institutional Review Board (HSIRB #NEU2490109A). Written informed consent was obtained from all participants.

**Study design**

This cross-sectional study aims to evaluate the clinical correlates of a large cohort of MS patients in relation to the CCSVI criteria [3]. The study represents a post-hoc analysis of the original Combined Transcranial and Extracranial Venous ECD Evaluation (CTEVD) study which was designed to assess the prevalence of CCSVI in a large cohort of patients with MS, healthy controls and controls with other neurological diseases (OND) using specific ECD criteria [3,9]. This CTEVD phase 1 study enrolled 289 MS and 21 clinically isolated syndrome (CIS) patients [9]. The participants received a clinical examination (BWG and DH, that were blinded to the Doppler findings) and an ECD scan of the head and neck (performed by a technician blinded to the subjects’ diagnosis) [9]. The clinical evaluation included neurological assessment using the Kurtzke Expended Disability Status Score (EDSS) based on its separate functional scores and gait endurance [26]. The EDSS was further converted to the MS Severity Scores (MSSS) scale that was designed as a comparative MS population disability assessment tool, to allow comparisons of relative disease severity at all EDSS levels for a given disease duration, using a single clinical assessment at a single point in time [27]. The ECD outcome measure of interest included the presence of CCSVI, as previously defined [3]. Additional ECD outcomes included the individual Doppler Criteria 1–5 and CCSVI severity, as measured by venous hemodynamic insufficiency severity score (VHISS) [3].

**Echo-color doppler data analysis**

Combined transcranial and extracranial ECD allows for non-invasive assessment of venous hemodynamic (VH) parameters indicative of CCSVI [3,4]. Cerebral venous return was examined by using the echo-color Doppler (ECD Esaote-Biosound My Lab 25) equipped with 2.5 and 7.5–10 Mhz transducers (Genoa, Italy), with the subject positioned on a tilt bed at 90° and 0° [3,4].

The specific details of subject length of exam, contraindications and limitations, subject assessment, examination guidelines, annotation documentation, specific Doppler parameters, criteria definitions, description of probes, positioning of the subject, hydration status, techniques used, fulfilment of VH criteria and pathology definitions are provided elsewhere [9].

Each subject was assigned a total criteria VH score that was calculated by counting the number of criteria that the subject fulfilled. A subject was considered CCSVI-positive if ≥2 VH criteria were fulfilled. Subjects who were not assessed for some VH criterion, due to technical difficulty, were assumed not to have fulfilled that criterion.

The five VH criteria evaluated are: Criterion 1) reflux in the IJVs and/or in the VVs assessed in both sitting and supine postures, Criterion 2) reflux in the deep cerebral veins (DCVs), Criterion 3) B-mode detection of stenoses in the IJVs in the form of annuli, webs, septa, or malformed valves, Criterion 4) absence of ECD signal in the IJV and/or in the VVs, even after forced deep breaths, and Criterion 5) presence of a negative difference in the cross sectional area (CSA) of the IJV. The severity of CCSVI was measured by VHISS, as previously reported [3]. VHISS is based on the sum of pathologic parameters measured for each of the 5 criteria examined. VHISS is ranging from 0 to 16.

**Data analysis**

SPSS (SPSS Inc., Chicago, IL, version 15.0) statistical program was used for all statistical analyses. The subjects with relapsing-remitting (RR) MS were categorized as non-progressive MS whereas subjects with relapsing and relapse-free forms of secondary progressive (SP) and primary-progressive (PP) MS were categorized as progressive MS.

One-way ANOVA followed by post-hoc independent sample t-tests were used to test for differences in means of continuous demographic variables such as age, age of onset, and disease duration. The χ² test was used for analysis of count variables for categorical data and the Fisher exact test was used where appropriate.
Logistic regression with the non-progressive vs. progressive MS status as the dependent variable, age as a covariate and gender as a factor was also used to assess the role of CCSVI. Analyses were conducted with main effects models containing CCSVI.

The EDSS values were dichotomized into EDSS ≥ 4 and EDSS < 4.0. The EDSS categories were analyzed as the dependent variable in logistic regression with sex and age and either presence of CCSVI or VHISS as predictors. The MSSS was analyzed as the dependent variable with linear regression with sex and age and either presence of CCSVI or VHISS as predictors, VHISS and number of venous hemodynamic criteria fulfilled were analyzed as dependent variable in Poisson regression with sex as a factor and age as a covariate. The EDSS sub-scores were analyzed with ordinal regression correcting for sex and age as a covariate, sex as a factor and either presence of CCSVI or VHISS as predictors.

In order to avoid too many spurious findings due to multiple comparisons, we do not report anything as statistically significant unless the nominal p-value was ≤ 0.01 by using two-tailed tests. A trend was assumed with Type 1 error level of 0.1.

Results

Demographic and clinical characteristics

The present analysis was restricted to adult subjects with RR-MS (n = 181), SP-MS (n = 80) and PP-MS (n = 12) disease courses. Healthy controls (n = 163), subjects with CIS (n = 21), pediatric-onset MS (n = 10), NMO (n = 6) and OND (n = 23) were excluded from the original cohort including 499 subjects [9].

Relapsing (n = 19) and non-relapsing SP-MS (n = 61) were grouped in to a single SP-MS category and similarly relapsing (n = 1) and non-relapsing primary (n = 11) progressive MS were grouped together in the PP-MS group. Table 1 shows demographic and clinical characteristics of the enrolled MS groups.

No age, sex or disease duration differences were found in the RR-MS and SP-MS in subjects either with or without the presence of CCSVI (all p > 0.05 in t-tests for age and disease duration and χ² test for sex differences, data not shown). The PP-MS patients with CCSVI were older (59.3 ± 6.3 years) than those without CCSVI (49.8 ± 6.8 years) but the sex distribution and disease duration were similar.

Of the 273 MS, 238/268 (88.8%) were on disease-modifying therapies; data were unavailable for 5 patients (Table 1). No differences in age at disease onset, disease diagnosis or number of relapses during the preceding year were seen between the CCSVI positive or negative groups (data not shown).

Disease state and CCSVI

Table 2 shows the prevalence of CCSVI classifications for MS patients by subtype of MS. The highest prevalence was seen in SP-MS, followed by PP-MS and RR-MS. In logistic regression correcting for age and sex, progressive MS (SP-MS or PP-MS) vs. non-progressive status (RR-MS) was associated with CCSVI diagnosis (p = 0.004, OR = 2.34, CI = 1.3–4.2).

As expected, VHISS was significantly higher for MS patients diagnosed with CCSVI (Mean ± SD: 4.20 ± 1.4) than for subjects without CCSVI (Mean ± SD: 1.28 ± 1.0; p < 0.001 from a Mann–Whitney test). Table 2 gives the distribution of VHISS for the MS disease groups. The MS disease groups (p < 0.001, Kruskall-Wallis) significantly differed in VHISS.

Disability status and CCSVI diagnosis

The three MS subtypes significantly differed on total EDSS score (p < 0.001, Kruskall-Wallis test) and all EDSS sub-scores (p < 0.001 for each, Kruskall-Wallis test). The probability of EDSS ≥ 4 was not associated with the presence of CCSVI (p = 0.42) in logistic regression correcting for age and sex. In ordinal regression correcting for sex and age, the presence of CCSVI diagnosis exhibited a trend with the EDSS brain stem sub-score (p = 0.074).

Table 1 gives the distribution of MSSS for the MS disease groups. No evidence for differences in mean MSSS ± SD for subjects diagnosed with CCSVI (4.17 ± 2.6) compared to subjects without CCSVI.

**Table 1** Demographic and clinical characteristics of the enrolled disease groups

| Demographic variables | All MS n = 273 | RR-MS n = 181 | SP-MS n = 80 | PP-MS n = 12 | p-value |
|-----------------------|---------------|---------------|--------------|--------------|---------|
| Females: Males (% Female) | 208: 65 (76.2%) | 138: 43 (76.2%) | 63: 17 (78.8%) | 7: 5 (58.3%) | 0.34 |
| Age, years | 47.7 ± 10.7 | 44.7 ± 10.0 | 53.3 ± 9.7 | 54.6 ± 8.0 | < 0.001 |
| Disease duration*, years | 15.2 ± 10.5 | 12.1 ± 8.3 | 21.9 ± 12.0 | 15.8 ± 9.4 | < 0.001 |
| Median EDSS* (IQR) | 3.0 (4.0) | 2.0 (1.5) | 6.0 (1.5) | 5.75 (3.13) | < 0.001 |
| MSSS | 4.05 ± 2.51 | 3.08 ± 2.12 | 5.87 ± 2.11 | 6.06 ± 2.71 | < 0.001 |
| Treatment duration, years | 3.8 ± 3.7 | 3.4 ± 3.5 | 4.8 ± 4.1 | 3.4 ± 3.0 | 0.03 |

* From symptoms.

Female to male ratio: χ² test; Age, disease duration, MSSS, treatment duration: one-way ANOVA; EDSS: Kruskal-Wallis test.

MS multiple sclerosis; PP primary progressive, RR relapsing-remitting; SP secondary progressive; IQR inter-quartile range; EDSS Expanded Disability Status Scale.
(3.88 ± 2.3, \( p = 0.60 \) from a Mann–Whitney test) were found. Similarly linear regression analyses (correcting for sex and age) did not show association with CCSVI (\( p = 0.49 \)).

**Disability status and CCSVI severity**

The VHISS exhibited a trend with increasing age (Slope B ± SE: 0.007 ± 0.0033, Wald \( \chi^2 = 4.54, p = 0.033 \)) in Poisson regression with sex as a factor and age as a covariate. However, there was no evidence for associations with EDSS.

VHISS was associated with the brainstem EDSS sub-score (\( p = 0.002 \)) and trends were found for the pyramidal (\( p = 0.026 \)) and cerebellar (\( p = 0.051 \)) sub-scores. The probability of EDSS \( \geq 4 \) was not associated with the severity of CCSVI as assessed by VHISS (\( p = 0.056 \)) in logistic regression correcting for age and sex.

**Discussion and conclusion**

The present study, a post hoc analysis of the original CTEVD study, which aimed primarily to determine the prevalence of CCSVI in MS patients, provides supplementary informative data to better understand the relation between MS and CCSVI criteria with a specific emphasis on disease and disability status. The original CTEVD study found no association between disease status and CCSVI diagnosis or any other CCSVI criteria. However, our large prevalence study showed higher frequency of CCSVI in progressive MS compared to relapsing MS, we did not obtain evidence for significant associations with disability. The divergence of the prevalence and disability data adds to the known difficulties of understanding and measuring the effects of the two key pathological mechanisms in MS – inflammatory vs. neurodegeneration – by introducing the presence of a VH dysfunction as a new variable. Hemodynamic venous dysfunction may result in secondary tissue hypoperfusion that may be associated with a continuous neurodegenerative process. Although VH dysfunction may be less related to the inflammatory aspects of the disease, we speculate that abnormal VH may progressively deteriorate in the context of the inflammatory milieu and activation of the vascular endothelium that occurs in MS [31]. Our previous findings in an OND group showing a high prevalence of CCSVI in the majority of patients diagnosed with inflammatory diseases (i.e., anti-phospholipid antibody syndrome, thyroiditis) [9]. CCSVI findings, if present at all, may reflect: i) benign anatomical variants ii) slower venous outflow due to global cerebral hypoperfusion or iii) alterations to venous walls secondary to a chronic inflammation milieu.

In conclusion, our results indicate that features of CCSVI have no relationship to disability in MS. Further prospective studies including multimodal analysis (i.e., MRI/MRV, ECD/TCD) may help in providing more light into the role of CCSVI or of VH dysfunction in MS.

### Table 2 CCSVI classification by MS subtype

| CCSVI Variables | All MS \( n = 273 \) | RR-MS \( n = 181 \) | SP-MS \( n = 80 \) | PP-MS \( n = 12 \) | \( p \)-value |
|-----------------|-----------------|-----------------|-----------------|-----------------|-------------|
| CCSVI diagnosis | 153 (56.0%)     | 89/181 (49.2%)  | 58/80 (72.5%)   | 6/12 (50.0%)    | 0.002       |
| Criterion 1   | 127 (46.5%)     | 76 (42.0%)      | 45 (56.2%)      | 6 (50.0%)       | 0.10        |
| Criterion 2   | 98 (35.9%)      | 53 (29.3%)      | 40 (50.0%)      | 5 (41.7%)       | 0.005       |
| Criterion 3   | 173 (63.4%)     | 115 (63.5%)     | 52 (65.0%)      | 6 (50.0%)       | 0.60        |
| Criterion 4   | 28 (10.3%)      | 12 (6.6%)       | 15 (18.8%)      | 1 (8.3%)        | 0.012       |
| Criterion 5   | 31 (11.4%)      | 12 (6.6%)       | 19 (23.8%)      | 0 (0%)          | < 0.001     |
| Number of abnormal criteria | 1.7 ± 1.1 | 1.5 ± 1.1 | 2.2 ± 1.0 | 1.5 ± 1.0 | < 0.001 |
| VHISS | 2.9 ± 1.9 | 2.6 ± 1.8 | 3.7 ± 2.0 | 2.5 ± 1.6 | < 0.001 |

*MS multiple sclerosis; PP primary progressive, PR progressive relapsing; RR relapsing-remitting, SP secondary progressive; VHISS venous hemodynamic insufficiency score.*
Competing interests
Dr. Weinstock-Guttman received compensation for speaking from Teva Neuroscience, Biogen Idec, EMD Serono and Novartis. She also received financial support for research activities from National Institute of Health, National Multiple Sclerosis Society, National Science Foundation, EMD Serono, Biogen Idec, Teva Neuroscience, Novartis, Cyberonics and the Jog for the Jake Foundation.

Murali Ramanathan received research funding or consulting fees from EMD Serono, Biogen Idec, Allergan, Netezza, Pfizer, Novartis, the National Multiple Sclerosis Society, the Department of Defense, Jog for the Jake Foundation, the National Institutes of Health and National Science Foundation. He received compensation for serving as an Editor from the American Association of Pharmaceutical Scientists. These are unrelated to the research presented in this report.

Ralph Benedict has received compensation for serving on Advisory Panels for Biogen, EMD Serono, Merck, Novartis, and Bayer. He has received CME funding from Bayer, Merck, and Biogen and grant support from NIMSS, NIH, Biogen, and Shire.

Dr. Zivadinov has received speaker honoraria and consultant fees from Teva Neurosciences, Biogen Idec, Questcor, Genzyme and EMD Serono; and received research support from the National Multiple Sclerosis Society, the Biogen Idec, Teva Neuroscience, Teva Pharmaceuticals, Genzyme, Questcor, Bracco and Greatbatch.

This study was funded by internal resources of the Buffalo Neuroimaging Analysis Center and Baird MS Center, the Jacobs Neurological Institute, University of Buffalo. In addition, we received support from the Direct MS Foundation, the Jacquemin Family Foundation and from smaller donors.

The results from the CTEVD study led to the organization of the IRB approved, unblinded, open-label descriptive study into CCSVI that included patients with either possible or definite MS. This fee-for-service registry study was designed to enhance utilization of data on venous anomalies obtained on individuals who sought information on CCSVI status. This study is no longer active.

Authors’ contributions
BW-G contributed to study design, oversaw all clinical aspects of the project including clinical data acquisition, data analysis and interpretation and manuscript preparation. MR contributed to study design, data analysis and interpretation and manuscript preparation, RZ contributed to study design, MRI data acquisition, data interpretation and manuscript preparation, KM contributed to study design, oversaw all clinical aspects of the project. All authors read and approved the final manuscript.

Author details
1Department of Neurology, State University of New York, Buffalo, NY, USA.
2Department of Biostatistics, University of Alabama, Birmingham, AL, USA.
3Department of Pharmaceutical Sciences, State University of New York, Buffalo, NY, USA. “Buffalo Neuroimaging Analysis Center, Department of Neurology, State University of New York, Buffalo, NY, USA.”
4Department of Neurology, State University of New York, Buffalo, E2 Neurology, Buffalo General Hospital, 100 High Street, Buffalo, NY 14203, USA.

Received: 3 August 2011 Accepted: 3 April 2012 Published: 15 May 2012

References
1. Frohman EM, Racke MK, Raine CS: Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med 2006, 354(9):942–955.
2. Frischer JM, Bramow S, Dal-Bianco A, Luccinetti CF, Rauschka H, Schmidtke KM, Laussen H, Soeren P, Sassmann H: The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009, 132(Pt 5):1175–1189.
3. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Tacconi G, Dall’Ara S, Bartolomei I, Salvi F: Chronic cerebrospinal venous insufficiency in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 2009, 80(4):392–399.
4. Zamboni P, Menegatti E, Galeotti R, Malagoni AM, Tacconi G, Dall’Ara S, Bartolomei I, Salvi F: The value of cerebral Doppler venous haemodynamics in the assessment of multiple sclerosis. J Neurol Sci 2009, 282(1–2):21–27.
5. Zamboni P, Menegatti E, Weinstock-Guttman B, Schirra C, Cox JL, Malagoni AM, Hojanzad D, Kennedy C, Carl E, Deyber MG, et al: The severity of chronic cerebrospinal venous insufficiency in patients with multiple sclerosis is related to altered cerebrospinal fluid dynamics. Funct Neurol 2009, 24(3):133–138.
6. Simka M, Kostekc J, Zaniewski M, Majewski E, Hartel M: Extracranial Doppler sonographic criteria of chronic cerebrospinal venous insufficiency in the patients with multiple sclerosis. Int Angiol 2010, 29(2):105–114.
7. Al-Omari MH, Rousan LA: Internal jugular vein morphology and hemodynamics in patients with multiple sclerosis. Int Angiol 2010, 29(2):115–120.
8. Yamout B, Herlopian A, Issa Z, Habbib RH, Fawaz A, Salame J, Wadih A, Awdeh H, Muaalem N, Raad R, et al: Extracranial venous stenosis is an unlikely cause of multiple sclerosis. Mult Scler 2010, 16(11):1341–1348.
9. Zivadinov R, Mar K, Catter G, Ramanathan M, Benedict RH, Kennedy C, Elfahal M, Yeh AE, Reuther J, Brooks C, et al: Prevalence, sensitivity, and specificity of chronic cerebrospinal venous insufficiency in MS. Neurology 2011, 77(2):138–144.
10. Monti L, Menci E, Ulivelli M, Cerese A, Bartalini S, Pu P, Moretti N, Leonini S, Galkuzzi P, Romano DG, et al: Quantitative ColourDopplerSonography evaluation of cerebral venous outflow: a comparative study between patients with multiple sclerosis and controls. PLoS One 2011, 6(9):e25012.
11. Zaharchuk G, Fischbein NJ, Rosenberg J, Herkens RJ, Dake MD: Comparison of MR and contrast venography of the cervical venous system in multiple sclerosis. AJNR Am J Neuroradiol 2011, 32(8):1482–1489.
12. Radak D, Tanaskovic S, Marinovic S, Antonic Z, Kolar J: Internal jugular vein duplication: a further truncular malformation in a patient with multiple sclerosis. Phlebology 2011 Oct 28. [Epub ahead of print]
13. Radak D, Kolar J, Tanaskovic S, Sagic D, Antonic Z, Mitrasinovic A, Babic S, Nenesic D, Iljevski N: Morphological and haemodynamic abnormalities in the jugular veins of patients with multiple sclerosis. Phlebology 2011 Sep 8. [Epub ahead of print]
14. Doepp F, Paul F, Valdueza JM, Schmierer W, Schreiber SI: No cerebrocerebral venous congestion in patients with multiple sclerosis. Ann Neurol 2010, 68(2):173–183.
15. Mayer CA, Pfleischfräter W, Lorenz MW, Nedelmann M, Bechmann I, Steinmetz H, Ziemann U: The perfect crime? CCSVI not leaving a trace in MS. J Neurol Neurosurg Psychiatry 2011, 82(3):436–440.
16. Baracchini C, Perini P, Causin F, Calabrese M, Rainaldi F, Gallo P: Progressive multiple sclerosis is not associated with chronic cerebrospinal venous insufficiency. Neurology 2011, 77(9):844–850.
17. Tsigoultis G, Mantatzis M, Bogiatzi C, Vakodialias K, Voumoulakis K, Pissapoulos P, Piperidou C, Heliopoulos I: Extracranial venous hemodynamics in multiple sclerosis: a case-control study. Neurology 2011, 77(13):1241–1245.
18. Auriel E, Kani A, Bornstein NM, Nissel T, Gadot O, Hallevi E: Extra-cranial venous flow in patients with multiple sclerosis. J Neurol Sci 2011, 309(1–2):102–104.
19. Marder E, Gupta P, Greenberg BM, Frohman EM, Awad AM, Bagert B, Stuve O: No cerebral or cervical venous insufficiency in US veterans with multiple sclerosis. Arch Neurol 2011, 68(2):1521–1526.
20. Zamboni P, Galeotti R, Menegatti E, Malagoni AM, Gianesini S, Bartolomei I, Mascoli F, Salvi F: A prospective open-label study of endovascular treatment of chronic cerebrospinal venous insufficiency. J Vasc Surg 2009, 50(6):1348–1358. e1341–e1343.
21. Neekes JA, Lee MJ, Bello AM, Barkhof F: Cardiovascular and interventional radiological society of Europe commentary on the treatment of chronic cerebrospinal venous insufficiency. Cardiovasc Intervent Radiol 2011, 34(1):1–2.
22. Krogias C, Schroder A, Wiend H, Hoffhölder R, Gold R: “Chronic cerebrospinal venous insufficiency” and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients. Nervenarzt 2010, 81(6):740–746.
23. Baracchini C, Perini P, Calabrese M, Causin F, Rinaldi F, Gallo P: No evidence of chronic cerebrospinal venous insufficiency at multiple sclerosis onset. Ann Neurol 2011, 69(1):90–99.

24. Singh AV, Zamboni P: Anomalous venous blood flow and iron deposition in multiple sclerosis. J Cereb Blood Flow Metab 2009, 29(12):1867–1878.

25. Zamboni P: The big idea: iron-dependent inflammation in venous disease and proposed parallels in multiple sclerosis. J R Soc Med 2006, 99(11):589–593.

26. Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983, 33(11):1444–1452.

27. Roxburgh RH, Seaman SR, Masterman T, Hensiek AE, Sawcer SJ, Vukusic S, Achiti I, Confavreux C, Coustans M, Le Page E, et al: Multiple sclerosis severity score: using disability and disease duration to rate disease severity. Neurology 2005, 64(7):1144–1151.

28. Bastianello S, Romani A, Viselner G, Colli Tibaldi E, Giugni E, Albieri M, Cecconi P, Mendozzi L, Farina M, Mariani D, et al: Chronic cerebrospinal venous insufficiency in multiple sclerosis: clinical correlates from a multicentre study. BMC Neurology 2011, 11:132.

29. Dolic K, Mari K, Valnarov V, Dwyer MG, Carl E, Karmen Y: Intra- and extraluminal structural and functional venous anomalies in multiple sclerosis, as evidenced by two non-invasive imaging techniques. Am J Neuroradiol 2011, press.

30. Centonze D, Floris R, Stefanini M, Rosi S, Fabiano S, Castelli M, Marzali S, Spinelli A, Motz C, Garaci FG, et al: Proposed chronic cerebrospinal venous insufficiency criteria do not predict multiple sclerosis risk or severity. Ann Neurol 2011, 70(1):52–59.

31. Minagar A, Carpenter A, Alexander JS: The destructive alliance: interactions of leukocytes, cerebral endothelial cells, and the immune cascade in pathogenesis of multiple sclerosis. Int Rev Neurobiol 2007, 79:1–11.

doi:10.1186/1471-2377-12-26

Cite this article as: Weinstock-Guttman et al.: Clinical correlates of chronic cerebrospinal venous insufficiency in multiple sclerosis. BMC Neurology 2012 12:26.